Click
here to close Hello! We notice that
you are using Internet Explorer, which is not supported by Echinobase
and may cause the site to display incorrectly. We suggest using a
current version of Chrome,
FireFox,
or Safari.
Mechanisms of Acquired Resistance to ALK Inhibitors and the Rationale for Treating ALK-positive Lung Cancer.
Isozaki H
,
Takigawa N
,
Kiura K
.
???displayArticle.abstract???
The discovery of an echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) fusion gene led to improved clinical outcomes in patients with lung cancer after the development of the first ALK-targeting agent, crizotinib. Some second-generation ALK tyrosine kinase inhibitors (TKIs), which might be more potent than crizotinib or effective on crizotinib-resistant patients, have been developed. Although these ALK-TKIs show an excellent response initially, most patients eventually acquire resistance. Therefore, careful consideration of the resistance mechanisms might lead to superior therapeutic strategies. Here, we summarize the history of ALK-TKIs and their underlying resistance mechanisms in both the preclinical and clinical settings. In addition, we discuss potential future treatment strategies in ALK-TKI-naïve and -resistant patients with lung cancer harboring the EML4-ALK fusion gene.
Ajimizu,
Rapid response of brain metastases to alectinib in a patient with non-small-cell lung cancer resistant to crizotinib.
2015, Pubmed
Ajimizu,
Rapid response of brain metastases to alectinib in a patient with non-small-cell lung cancer resistant to crizotinib.
2015,
Pubmed
Awad,
ALK inhibitors in non-small cell lung cancer: crizotinib and beyond.
2014,
Pubmed
Branford,
High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance.
2002,
Pubmed
Butrynski,
Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.
2010,
Pubmed
Camidge,
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.
2012,
Pubmed
Chen,
LDK378: a promising anaplastic lymphoma kinase (ALK) inhibitor.
2013,
Pubmed
Cheng,
CEP-28122, a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase with antitumor activity in experimental models of human cancers.
2012,
Pubmed
Choi,
EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.
2010,
Pubmed
,
Echinobase
D'Incecco,
PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients.
2015,
Pubmed
Debelenko,
Renal cell carcinoma with novel VCL-ALK fusion: new representative of ALK-associated tumor spectrum.
2011,
Pubmed
Doebele,
Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.
2012,
Pubmed
Friboulet,
The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.
2014,
Pubmed
Gadgeel,
Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.
2014,
Pubmed
Gainor,
Alectinib salvages CNS relapses in ALK-positive lung cancer patients previously treated with crizotinib and ceritinib.
2015,
Pubmed
Gambacorti-Passerini,
Crizotinib in anaplastic large-cell lymphoma.
2011,
Pubmed
Gatalica,
Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type.
2014,
Pubmed
Giri,
Novel mutations in a patient with ALK-rearranged lung cancer.
2014,
Pubmed
Griffin,
Recurrent involvement of 2p23 in inflammatory myofibroblastic tumors.
1999,
Pubmed
Ignatius Ou,
Next-generation sequencing reveals a Novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802/RO5424802) in ALK-rearranged NSCLC patients who progressed on crizotinib.
2014,
Pubmed
Jazii,
Identification of squamous cell carcinoma associated proteins by proteomics and loss of beta tropomyosin expression in esophageal cancer.
2006,
Pubmed
Katayama,
Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK.
2011,
Pubmed
,
Echinobase
Katayama,
Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.
2012,
Pubmed
Katayama,
Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib.
2014,
Pubmed
Kobayashi,
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.
2005,
Pubmed
Kodama,
Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance.
2014,
Pubmed
Kodama,
Alectinib shows potent antitumor activity against RET-rearranged non-small cell lung cancer.
2014,
Pubmed
Kodama,
Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases.
2014,
Pubmed
Lin,
Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers.
2009,
Pubmed
,
Echinobase
Lovly,
Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer.
2014,
Pubmed
Lovly,
Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors.
2011,
Pubmed
Lynch,
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
2004,
Pubmed
Maemondo,
Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.
2010,
Pubmed
Mariño-Enríquez,
ALK rearrangement in sickle cell trait-associated renal medullary carcinoma.
2011,
Pubmed
Morris,
Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma.
1994,
Pubmed
Mossé,
Identification of ALK as a major familial neuroblastoma predisposition gene.
2008,
Pubmed
Murugan,
Anaplastic thyroid cancers harbor novel oncogenic mutations of the ALK gene.
2011,
Pubmed
O'Brien,
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.
2003,
Pubmed
Ohashi,
Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease.
2013,
Pubmed
Ou,
Alectinib induces a durable (>15 months) complete response in an ALK-positive non-small cell lung cancer patient who progressed on crizotinib with diffuse leptomeningeal carcinomatosis.
2015,
Pubmed
Paez,
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.
2004,
Pubmed
Pao,
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain.
2005,
Pubmed
Powers,
Pleiotrophin signaling through anaplastic lymphoma kinase is rate-limiting for glioblastoma growth.
2002,
Pubmed
Sakamoto,
CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant.
2011,
Pubmed
Sasaki,
The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers.
2010,
Pubmed
Sasaki,
A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors.
2011,
Pubmed
Seto,
CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study.
2013,
Pubmed
Shaw,
Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.
2013,
Pubmed
Shaw,
Ceritinib in ALK-rearranged non-small-cell lung cancer.
2014,
Pubmed
Soda,
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.
2007,
Pubmed
,
Echinobase
Solomon,
First-line crizotinib versus chemotherapy in ALK-positive lung cancer.
2014,
Pubmed
Stoica,
Identification of anaplastic lymphoma kinase as a receptor for the growth factor pleiotrophin.
2001,
Pubmed
Sugawara,
Identification of anaplastic lymphoma kinase fusions in renal cancer: large-scale immunohistochemical screening by the intercalated antibody-enhanced polymer method.
2012,
Pubmed
Sukov,
ALK alterations in adult renal cell carcinoma: frequency, clinicopathologic features and outcome in a large series of consecutively treated patients.
2012,
Pubmed
Toyokawa,
Dramatic response to crizotinib in an ALK-positive adenocarcinoma patient with disseminated intravascular coagulation.
2013,
Pubmed
Toyokawa,
Secondary mutations at I1171 in the ALK gene confer resistance to both Crizotinib and Alectinib.
2014,
Pubmed
Vaishnavi,
Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer.
2013,
Pubmed
Yaakup,
Primary oesophageal Ki (CD30)-positive ALK+ anaplastic large cell lymphoma of T-cell phenotype.
2008,
Pubmed
Yamada,
Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor resistance in EML4-ALK lung cancer cells.
2012,
Pubmed
